

Asthma

**A study of a new medicine for asthma and cough: GDC-6599, a TRPA1 inhibitor**

<b>Trial Status</b> Completed	<b>Trial Runs In</b> 1 Countries	<b>Trial Identifier</b> 2021-002464-48 GA43010
----------------------------------	-------------------------------------	---

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

***Trial Summary:***

This clinical trial was done to study a new medicine, “GDC-6599,” for the treatment of people with asthma. This study was done to look at side effects at different doses and learn about whether this medicine was safe and could be tolerated by people. Researchers also wanted to learn about the effect of food on this medicine and whether it had any effect on the cell structure it was targeting. This was a phase 1, placebo-controlled, randomized, double-blind, dose-escalation study that was conducted at one study center in the Netherlands.

<b>Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)</b> Sponsor	<b>Phase 1</b> Phase
--	-------------------------

---

**2021-002464-48 GA43010**  
Trial Identifiers

---

***Eligibility Criteria:***

<b>Gender</b> All	<b>Age</b> 18 to 75 years	<b>Healthy Volunteers</b> Yes
----------------------	------------------------------	----------------------------------

---

GDC-6599, a new TRPA1 inhibitor, is under development for the treatment of asthma and cough. This trial was conducted at a single study center in the Netherlands, involving 81 healthy volunteers. Some were given GDC-6599. Others were given a fake medicine (placebo) that did not have any real medicine in it. Results from the study showed no serious side effects. Thirteen people had non-serious side effects that doctors thought were related to the treatments.